Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant versus tamoxifen in hormone receptor-positive early breast cancer after discontinuation of adjuvant aromatase inhibitor therapy due to toxicity
2021-000398-10Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Amcenestrant with Tamoxifen (2 arms). Primary endpoint: Invasive breast cancer-free survival. Started Feb 2022; status: completed.
02
Drugs
amcenestranttamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-000398-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000398-10.